2021年12月29日格林尼治时间07:00
澳门葡京网赌游戏(澳门葡京网赌游戏)已关闭了一笔交易 global 发展 and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX.
The companies will jointly develop and commercialise eplontersen in the US, while 澳门葡京网赌游戏 will develop and commercialise it in the rest of the world, 除了拉丁美洲.
金融方面的考虑
Under the terms of the agreement, the upfront payment from 澳门葡京网赌游戏 to Ionis is $200m. 澳门葡京网赌游戏 will make additional conditional payments of up to $485m following regulatory approvals. 它还将支付高达2美元的费用.9bn of sales-related milestones based on sales thresholds between $500m and $6bn, plus royalties in the range of low double-digit to mid-twenties percentage depending on the region. The collaboration includes territory-specific 发展, commercial and medical affairs cost-sharing provisions.
The transaction will be funded with cash and is expected to be neutral to Core earnings in 2021. It will be accounted for as an intangible asset acquisition, recognised initially at the upfront amount, with any potential future milestone payments capitalised into the intangible asset as they are recognised.
Ionis will continue to manufacture and supply eplontersen for the existing clinical studies and process qualification. 澳门葡京网赌游戏 will be responsible for commercial supply, with transition timing to be agreed by both parties. 澳门葡京网赌游戏 will book all sales generated under the agreement.
The transaction does not impact 澳门葡京网赌游戏’s financial guidance for 2021.
笔记
Eplontersen
Eplontersen is a ligand-conjugated antisense (LICA) investigational medicine designed to reduce the production of transthyretin, 或TTR蛋白, to treat all types of TTR amyloidosis (ATTR), 一个系统, progressive and fatal disease.
淀粉样变(ATTR)
Cardiomyopathy and polyneuropathy due to ATTR are caused by aging or genetic mutations resulting in misfolded TTR protein and accumulation as amyloid fibrils in the cardiac myocardium and peripheral nerves, 分别. 在ATTR患者中, both the mutant and wild type TTR protein builds up as fibrils in tissues, 比如周围神经, 心, 消化系统, 眼睛, 肾脏, 中枢神经系统, 甲状腺和骨髓. The presence of TTR fibrils interferes with the normal functions of these tissues. As the TTR protein fibrils enlarge, more tissue damage occurs and the disease worsens, resulting in poor quality of life and eventually death. 在世界范围内, 估计有300只,000 - 500,000 patients with amyloid transthyretin cardiomyopathy (ATTR-CM)1,2 and 10,000 - 40,000 patients with amyloid transthyretin polyneuropathy (ATTR-PN).3
澳门葡京网赌游戏
澳门葡京网赌游戏 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门葡京赌博游戏, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门葡京网赌游戏 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门葡京网赌游戏.com and follow the Company on 推特 @澳门葡京网赌游戏.
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.
参考文献
1. Mohamed-Salem L, 等. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. 心脏内科. 2018年11月1日;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2. Cuscaden C, 等. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J核心醇. 2020年5月8日. doi: 10.1007/s12350-020-02152-x.
3. Gonzalez-Duarte, 等. Impact of non-cardiac clinicopathologic characteristics on survival in transthyretin amyloid polyneuropathy. 神经其他计划. 2020;9(1):135-149. doi: 10.1007/s40120-020-00183-7.
艾德里安·坎普
公司秘书
澳门葡京网赌游戏